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Abstract
Background: Pulmonary valve endocarditis without the involvement of other valves represents 1.5-2% of all cases
of infective endocarditis. Isolated pulmonary valve endocarditis caused by Candida is extremely rare with only one
reported case in the literature and none reported in the United States. Guidelines for management of Candida
endocarditis recommend a combination of medical and surgical therapy.
Case presentation: A 61-year-old homeless male presented with fever, cough and shortness of breath. He was urgently
intubated for hypoxia. He was initially diagnosed with pneumonia but did not improve with empiric antibacterial
therapy. Candida species were isolated from bronchoalveolar lavage fluid and the patient eventually developed
persistent C. albicans bloodstream infection. On further workup he was found to have infective endocarditis with
a large vegetation across the pulmonary valve. No other valves were involved. He was treated with intravenous
antifungal therapy for eight weeks. Valvular surgery was not performed. Follow up echocardiography after completion
of therapy did not show any vegetations and the patient clinically improved.
Conclusion: This is the second reported case of isolated pulmonary valve endocarditis caused by Candida and the first
to be successfully managed with antifungal therapy alone. Pulmonary valve endocarditis should be considered in cases
of pneumonia with Candida and persistent fungemia. While surgery should be considered in all cases of Candida
endocarditis, cure may be achieved with antifungal therapy alone.
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Background
Pulmonary valve endocarditis without the involvement
of other valves represents 1.5-2% of all cases of infective
endocarditis [1]. Fungal endocarditis is also rare, com-
prising <10% of all endocarditis cases [2]. Despite the
development of newer antifungal agents, mortality from
Candida endocarditis is estimated to be 30-37% [3-5].
The Infectious Diseases Society of America 2009 candid-
iasis guidelines recommend a combined medical and
surgical approach for treatment of Candida endocarditis
[6]. There has been only one reported case of isolated
pulmonary valve endocarditis with Candida which was
managed surgically [7]. We report a case of isolated
pulmonary valve endocarditis due to Candida managed
with medical therapy alone.
Case presentation
A 61 year-old homeless African-American male was
admitted to the intensive care unit with fever, dyspnea, and
hemoptysis for four days. He had a history of depression
and active intravenous drug use. Physical examination was
positive for crackles in both lung fields. He had no track
marks on his skin. His white blood cell (WBC) count was
0.3 × 103/μL with absolute neutrophil count 100/mm3.
Urine toxicology screen was positive for opiates and benzo-
diazepines. His basic metabolic panel was normal but his
arterial blood gas (ABG) analysis revealed a PaO2 of 62 mm
Hg on room air. He was intubated in the emergency room
for hypoxia. Computed tomography (CT) scan of the chest
revealed large patchy opacities in the right upper and
middle lobes consistent with pneumonia and no evidence
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of pulmonary embolism (Figure 1A). Empiric vancomycin
and piperacillin-tazobactam were started. His initial blood
cultures and serum HIV ELISA antibody were negative.
Three tracheal aspirate specimen smears were negative for
acid-fast bacilli.
Bronchoscopy performed on hospital day three showed
black secretions from the right lower lobe. He was started
on Micafungin after bronchoalveolar lavage cultures
grew Candida albicans and Candida glabrata. Trans-
bronchial biopsy was not performed due to friable
mucosa. Trans-thoracic echocardiogram on hospital day
five revealed no valvular abnormalities or vegetations.
Because of persistent fever and hypoxia, a second bron-
choscopy was performed on hospital day eight, which
still showed black secretions; bronchoalveolar lavage
cultures grew Candida glabrata. Two sets of blood cultures
collected on hospital day twelve grew Candida albicans. A
central venous catheter that had been placed on admission
was removed; culture of the catheter tip showed no
growth. Amphotericin B lipid complex was initially added
to Micafungin. After his creatinine rose from 0.9 to 4.5
mg/dL, this was switched to Liposomal Amphotericin B;
his creatinine normalized to 1.1 mg/dL by hospital day
thirty. Additionally, his WBC count rose to 4.9 × 103/μL
with 68% neutrophils calculated on an automated differen-
tial with no interventions other than treating his underlying
sepsis. The patient defervesced three days after ampho-
tericin B was added and Micafungin was discontinued.
However, repeat blood cultures on hospital day fourteen
again grew Candida albicans. A trans-esophageal echo-
cardiogram (TEE) performed on hospital day sixteen
showed a 1.5 cm mobile mass on the pulmonary valve
extending from the right ventricular outflow tract across
the pulmonary valve into the pulmonary artery (Figure 2A).
A diagnosis of isolated pulmonary valve endocarditis
secondary to Candida was made. Cardiothoracic surgery
was consulted; they advised medical therapy and later
re-evaluation as the patient was a high-risk candidate
for surgery. Blood cultures obtained on hospital day 16
had no growth. After a tracheostomy was performed, the
patient was transferred to a nursing home to complete
liposomal amphotericin B for a total of eight weeks. His
repeat CT chest at the time of discharge showed complete
resolution of pulmonary infiltrates (Figure 1B) and he was
weaned to tracheal mask. Lifelong suppressive oral flu-
conazole therapy was recommended. After eight weeks
of antifungal therapy, a repeat TEE did not show any
pulmonary valve vegetation (Figure 2B). The patient
clinically improved, his tracheostomy was closed, and
he was discharged back to the shelter. Six months after
discharge, the patient was asymptomatic and doing
well. He had stopped taking his oral fluconazole despite
recommendations for lifelong suppressive therapy.
Discussion
This report illustrates an unusual case of isolated pulmon-
ary valve endocarditis with Candida in an intravenous
drug user that was managed successfully with medical
therapy alone. Isolated pulmonary valve endocarditis is
rare [8]. Endocarditis in an intravenous drug user usually
involves the tricuspid valve, but a structurally normal
pulmonic valve is rarely the only one affected [9]. Possible
reasons for this are twofold. First, the lower pressure
gradient across the pulmonic valve leads to less shear
stress compared to the other valves [10,11]. This causes
less valvular damage, making it less vulnerable for
endocarditis. Second, valvular abnormalities (congenital
or acquired) are less common in the pulmonary valve.
An autopsy analysis of nine cases of isolated pulmonary
valve infective endocarditis revealed seven cases had
congenital heart disease and five cases had septic pul-
monary emboli [12]. It is unclear if our patient had a
primary Candida pneumonia leading to endocarditis or
a Candida blood stream infection with endocarditis and
septic pulmonary emboli. We do not have a trans-bronchial
biopsy to confirm a diagnosis of Candida pneumonia,
Figure 1 Computed tomography of the chest. A. Patchy opacities inthe right lung. B. Resolution of the opacities after intravenous Amphotericin B.
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which is by itself, is rare [13]. A patient with suspected
Candida pneumonia should have a work-up for right-sided
endocarditis.
The only other reported case of isolated pulmonary
valve endocarditis due to Candida described a 66-year-old
man with C. parapsilosis fungemia. In that case, a two-
stage operation was performed: initial resection of the
pulmonary valve leaflets with vegetations and subsequent
valve replacement two years later [7]. Current endocarditis
guidelines recommend initial or induction therapy with
amphotericin B with or without flucytosine with surgical
removal of vegetation, followed by chronic suppressive
therapy with oral fluconazole [14]. Although he had a
large fungal vegetation, our patient did not have any other
indications for surgery, such as congestive heart failure,
valve dehiscence, or peri-valvular abscess [14]. His chest
radiography did not reveal evidence of new septic emboli
once therapy was started and his blood cultures sterilized
soon after the diagnosis of endocarditis was made. There
is conflicting data on outcomes associated with the
combined medical and surgical approach versus med-
ical therapy alone [15]. Because patients with Candida
endocarditis often have other co-morbidities that affect
the decision to operate and their outcomes, the optimal
management is unclear. However, there have been reports
of successful therapy of Candida endocarditis with anti-
fungal medical therapy without surgical intervention [16].
Fluconazole and amphotericin B both target ergosterol,
a component of the fungal cell membrane. Treating
Candida endocarditis can be difficult because Candida
species can form biofilms on native and prosthetic
heart valves that can lead to the poor antifungal activity
of these agents. The resistance occurs through multiple
mechanisms, including decreasing the cell membrane
content of ergosterol. The newer antifungal agents, such as
amphotericin B lipid formulations and the echinocandins,
exhibit novel activity and may be more efficacious
against Candida biofilms [17]. Combination therapy with
echinocandins and lipid formulations of amphotericin B
may be able to treat Candida endocarditis while limit-
ing the emergence of resistance [18]. This may obviate
the need for surgical removal of the fungal vegetation.
Conclusion
Persistent Candida in respiratory cultures without other
etiologies for sepsis may be a sign of right-sided Candida
endocarditis. Aggressive medical management of this rare
condition may be successful with newer antifungal agents
that have activity against Candida biofilms. Medical ther-
apy without surgical intervention deserves consideration,
especially in cases where surgery may not be an option.
However, such patients should be monitored closely for
signs of treatment failure on medical therapy alone, such
as septic embolization.
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Figure 2 Transesophageal echocardiogram. A. Pulmonary valve vegetation B. No vegetation after four weeks of Amphotericin B.
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